Page 308 - Read Online

Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 13 of 18

J Med 2005;352:1779-90.
16. Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs 2015;75:297-308.
17. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N
Engl J Med 2012;366:799-807.
18. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, et al. Long-term findings from COMFORT-II, a phase 3 study of
ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30:1701-7.
19. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, et al. Ruxolitinib versus standard therapy for the treatment of
polycythemia vera. N Engl J Med 2015;372:426-35.
20. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in
patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol 2017;96:1113-20.
21. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in
patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513-20.
22. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, et al. Ruxolitinib versus best available therapy in patients with
polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016;101:821-9.
23. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci 2018;27:1984-
2009.
24. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-3.
25. Liongue C, Ward AC. Evolution of the JAK-STAT pathway. JAK-STAT 2013;2:e22756.
26. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst 2006;2:536-50.
27. Alvarez JV, Frank DA, Alvarez J, Lab F. Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated
oncogenesis. Cancer Biol Ther 2004;3:1045-50.
28. Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system.
Cancer Lett 2018;415:117-28.
29. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol 2001;70:348-56.
30. Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A. Suppressors of cytokine signaling: potential immune checkpoint molecules for
cancer immunotherapy. Cancer Sci 2017;108:574-80.
31. Niu GJ, Xu JD, Yuan WJ, Sun JJ, Yang MC, et al. Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK/STAT pathway
by inhibiting STAT phosphorylation and translocation. Front Immunol 2018;9:2392.
32. Frankson R, Yu ZH, Bai Y, Li Q, Zhang RY, et al. Therapeutic targeting of oncogenic tyrosine phosphatases. Cancer Res 2017;77:5701-5.
33. Kim M, Morales LD, Jang IS, Cho YY, Kim DJ. Protein tyrosine phosphatases as potential regulators of STAT3 signaling. Int J Mol Sci
2018;19:2708.
34. Chen YW, Guo T, Shen L, Wong KY, Tao Q, et al. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for
tumor suppression in nasal NK/T-cell lymphoma. Blood 2015;125:1589-600.
35. Lee M, Hirpara JL, Eu JQ, Sethi G, Wang L, et al. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors. Redox
Biol 2019;25:101073.
36. Zhang X, Guo A, Yu J, Possemato A, Chen Y, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc
Natl Acad Sci U S A 2007;104:4060-4.
37. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently
inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009;106:9435-40.
38. Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in
cancer. Cancer Sci 2018;109:926-33.
39. Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell
large granular lymphocytic leukemia. Hum Pathol 2018;73:74-81.
40. Yang S, Luo C, Gu Q, Xu Q, Wang G, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in
hepatocellular carcinoma. Oncotarget 2016;7:5461-9.
41. Kan Z, Zheng H, Liu X, Li S, Barber TD, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Genome Res 2013;23:1422-33.
42. Igelmann S, Neubauer HA, Ferbeyre G. STAT3 and STAT5 activation in solid cancers. Cancers (Basel) 2019;11:1428.
43. Orlova A, Wagner C, De Araujo ED, Bajusz D, Neubauer HA, et al. Direct targeting options for STAT3 and STAT5 in cancer. Cancers
(Basel) 2019;11:1930.
44. Wang Y, Wu C, Zhang C, Li Z, Zhu T, et al. TGF-β-induced STAT3 overexpression promotes human head and neck squamous cell
carcinoma invasion and metastasis through malat1/miR-30a interactions. Cancer Lett 2018;436:52-62.
45. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, et al. STAT3 activation abrogates growth factor dependence and
contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13:355-62.
46. Bu LL, Yu GT, Wu L, Mao L, Deng WW, et al. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. J Dent Res
2017;96:1027-34.
47. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, et al. STAT3 is constitutively activated and supports cell survival in association with
survivin expression in gastric cancer cells. Oncogene 2004;23:4921-9.
48. Wu X, Tao P, Zhou Q, Li J, Yu Z, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017;8:20741-50.